{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:56:32Z","timestamp":1782255392017,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Paolo Nuciforo and Jose Jimenez for excellent technical assistance with FFPE and immunohistochemistry"},{"name":"Marta Vilaro for statistical support and Francisco S\u00e1nchez V\u00e9lez for graphic design"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.lungcan.2016.03.001","type":"journal-article","created":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T03:33:12Z","timestamp":1457580792000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Analysis of expression of PTEN\/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)"],"prefix":"10.1016","volume":"96","author":[{"given":"S.","family":"Cedr\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ponce-Aix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Pardo-Aranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Navarro-Mendivil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Martinez-Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zugazagoitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Sansano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Montoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Enguita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2016.03.001_bib0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0003-4975(10)60182-8","article-title":"Pleural mesothelioma","volume":"43","author":"Martini","year":"1987","journal-title":"Ann. Thorac. Surg."},{"issue":"14","key":"10.1016\/j.lungcan.2016.03.001_bib0010","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0015","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"Van Meerbeeck Gaafar","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.lungcan.2016.03.001_bib0020","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.lungcan.2005.03.015","article-title":"Induction chemotherapy, extrapleural pneumonectomy, andradiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience","volume":"49","author":"Flores","year":"2005","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2016.03.001_bib0025","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.2008.17.5604","article-title":"Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma","volume":"2027","author":"de Perrot","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0030","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/0008-5472.CAN-04-4567","article-title":"Functional analysis of c-Met\/hepatocyte growth factor pathway in malignant pleural mesothelioma","volume":"66","author":"Jagadeeswaran","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0035","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2005.10.016","article-title":"EGFR overexpression in malignant pleural mesothelioma: an immunohistochemical and molecular study with clinico-pathological correlations","volume":"51","author":"Destro","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2016.03.001_bib0040","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/bjc.1990.207","article-title":"Malignant pleural mesothelioma and epidermal growth factor receptor (EGFR). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody","volume":"61","author":"Dazzi","year":"1990","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2016.03.001_bib0045","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1046\/j.1365-2559.2000.00888.x","article-title":"Immunoreactivity for cadherins, HGF\/SF, met, and erbB-2 in pleural malignant mesotheliomas","volume":"36","author":"Thirkettle","year":"2000","journal-title":"Histopathology"},{"key":"10.1016\/j.lungcan.2016.03.001_bib0050","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1158\/0008-5472.CAN-04-1898","article-title":"Selective activation of Insulin Receptor Substrate-1 and \u22122 in pleural mesothelioma cells: association with distinct malignant phenotypes","volume":"64","author":"Hoang","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0055","doi-asserted-by":"crossref","first-page":"455S","DOI":"10.1378\/chest.116.suppl_3.455S","article-title":"Emerging translational therapies for mesothelioma","volume":"116","author":"Pass","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2016.03.001_bib0060","first-page":"627","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nature Reviews"},{"issue":"9","key":"10.1016\/j.lungcan.2016.03.001_bib0065","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/JTO.0b013e31811f3aab","article-title":"Ras pathway activation in malignant mesothelioma","volume":"2","author":"Patel Mr Jacobson","year":"2007","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0070","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1038\/sj.onc.1209085","article-title":"Perturbations of the AKT signaling pathway in human cancer","volume":"24","author":"Altomare","year":"2005","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.lungcan.2016.03.001_bib0075","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/JTO.0000000000000055","article-title":"Frischknecht l, et al: pI3K\/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy","volume":"9","author":"Bitanihirwe","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0080","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumor microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0085","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0090","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0095","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity and immune correlates of anti-PD1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0100","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0105","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.3000","article-title":"A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors","volume":"31","author":"Herbst","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0110","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0115","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1158\/1078-0432.CCR-04-0428","article-title":"B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression","volume":"10","author":"Konishi","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0120","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-04-1469","article-title":"Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer","volume":"11","author":"Ohigashi","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0125","first-page":"6501","article-title":"B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma","volume":"63","author":"Strome","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0130","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1073\/pnas.0406351101","article-title":"Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target","volume":"101","author":"Thompson","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0135","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0140","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00767.x","article-title":"PD-1 signaling in primary T cells","volume":"229","author":"Riley","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0145","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0150","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nm1517","article-title":"Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma","volume":"13","author":"Parsa","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0155","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0160","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors","volume":"30","author":"Akbay","year":"2013","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.lungcan.2016.03.001_bib0165","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/onc.2008.384","article-title":"PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer","volume":"28","author":"Crane","year":"2009","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.lungcan.2016.03.001_bib0170","first-page":"1","article-title":"the activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition","volume":"19","author":"Yiang","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0175","doi-asserted-by":"crossref","first-page":"121171","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of PD-L1 in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedr\u00e9s","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2016.03.001_bib0180","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0185","series-title":"TNM Classification of Malignant Tumors","article-title":"International Uniona Against Cancer","year":"2009"},{"key":"10.1016\/j.lungcan.2016.03.001_bib0190","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.lungcan.2012.02.022","article-title":"Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM)","volume":"77","author":"Cedr\u00e9s","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2016.03.001_bib0195","first-page":"1","article-title":"PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells","author":"Mahoney","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0200","doi-asserted-by":"crossref","first-page":"65821","DOI":"10.1371\/journal.pone.0065821","article-title":"PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer","volume":"8","author":"Song","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2016.03.001_bib0205","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ccr.2014.03.033","article-title":"loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression","volume":"12","author":"Xu","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2016.03.001_bib0210","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-0016","article-title":"Induction of PD-L1 expression by the EML-ALK oncoprotein and dowstream signaling pathways in non-small cell lung cancer","volume":"15","author":"Ota","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0215","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/bjc.2014.555","article-title":"PD-1 and PD-L1 expression in mocelularly selected non-small cell lung cancer patients","volume":"112","author":"D\u0301Incecco","year":"2015","journal-title":"Brit. J. Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2016.03.001_bib0220","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1111\/j.1349-7006.2009.01302.x","article-title":"B7-H1 expression is regulated by MEK\/ERK signaling pathway in anaplastic large cell lymphoma and Hodking lymphoma","volume":"100","author":"Yamamoto","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0225","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1158\/1078-0432.CCR-13-2797","article-title":"Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma","volume":"20","author":"Atefi","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0230","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.8012","article-title":"Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC)","volume":"33","author":"Gainor","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0235","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1158\/1078-0432.CCR-04-0428","article-title":"B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression","volume":"10","author":"Konishi","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0240","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1158\/1078-0432.CCR-04-1469","article-title":"Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer","volume":"11","author":"Ohigashi","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0245","first-page":"6501","article-title":"B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma","volume":"63","author":"Strome","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0250","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1073\/pnas.0406351101","article-title":"Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target","volume":"101","author":"Thompson","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lungcan.2016.03.001_bib0255","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1158\/1078-0432.CCR-09-1652","article-title":"Tumor-expressed B7-H1 and B7-DC in relation to PD-1\u00fe T-cell infiltration and survival of patients with cervical carcinoma","volume":"15","author":"KarimR. Jordanova","year":"2009","journal-title":"Clin. Cancer Res."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216302379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216302379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T23:15:39Z","timestamp":1600298139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500216302379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":51,"alternative-id":["S0169500216302379"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.03.001","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of expression of PTEN\/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}